Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
-
Published:2020-04
Issue:4
Volume:77
Page:548-556
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Necchi AndreaORCID, Madison Russell, Raggi Daniele, Jacob Joseph M.ORCID, Bratslavsky Gennady, Shapiro Oleg, Elvin Julia A., Vergilio Jo-Anne, Killian Jonathan K., Ngo Nhu, Ramkissoon Shakti, Severson Eric, Hemmerich Amanda C., Huang Richard, Ali Siraj M., Chung Jon H., Reddy PrasanthORCID, Miller Vincent A., Schrock Alexa B., Gay Laurie M., Alexander Brian M., Grivas Petros, Ross Jeffrey S.
Reference35 articles.
1. Anti-programmed cell death 1/ligand 1 (PD-1/PD-L1) antibodies for the treatment of urothelial carcinoma: state of the art and future development;Powles;Clin Genitourin Cancer,2018 2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016 3. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017 4. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017 5. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol,2017
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|